LEAWOOD, Kan., June 11, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX ), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved an additional vial size (10 mL) for NOCITA ® (bupivacaine liposome injectable suspension). NOCITA is currently available in a 20 mL vial size and Aratana continues to anticipate commercial availability of the NOCITA 10 mL vial by fall 2019. "Since its launch in 2016, Nocita has drastically changed veterinary multimodal pain management protocols because it safely and effectively controls pain in patients for up to 72 hours following certain canine and feline surgeries," states Dr. Ernst Heinen, Chief Development Officer for Aratana Therapeutics.